Skip to main content
. Author manuscript; available in PMC: 2024 Jan 4.
Published in final edited form as: Cancer. 2022 Jun 6;128(15):2967–2977. doi: 10.1002/cncr.34263

Table 4:

Cohort 2 Disease Response and Outcome According to Bridge Regimen

Bridge Regimens Pt (n) End-Induction Overall
INRC Response
(n)		 End-of- Bridge Overall INRC Response
(n)		 2-year EFS
2-year OS
(95%CI)		 3-year EFS
3-year OS
(95%CI)		 5-year EFS
5-year OS
(95% CI)
Regimen contains DIT without MIBG 22 CR: 0
PR: 7
MR: 11
SD: 4		 CR: 8
PR: 11
MR: 3
SD: 0		 67.8% (41.7–84.2)
95.2% (70.7–99.3)		 52.7% (26.3–73.6)
87.3% (56.4–96.8)		 N/A
Regimen contains MIBG without DIT 20 CR: 0
PR: 7
MR: 9
SD: 4		 CR: 1
PR: 13
MR: 6
SD: 0		 75.0% (50.0–88.7)
95% (69.5–99.3)		 50.0% (27.1–69.2)
85.0% (60.4–94.9)		 50.0% (27.1–69.2)
63.5% (38.0–80.8)
Regimen contains both MIBG and DIT 2 SD: 2 CR: 1
PR: 1		 100%
100%		 100%
100%		 N/A
Regimen without MIBG and DIT 7 CR: 0
PR: 4
MR: 3
SD: 0		 CR: 2
PR: 2
MR: 1
SD: 1
1Unknown:1		 85.7% (33.4–97.9)
100%		 57.1% (17.2–30.5)
85.7% (33.4–97.9)		 57.1% (17.2–30.5)
51.4% (11.8–81.3)

Abbreviations: CR, complete response; DIT, dinutuximab, irinotecan, and temozolomide; EFS, event-free survival; INRC, International Neuroblastoma Response Criteria; MIBG, meta-iodobenzylguanidine; MR, minor response; NA, not applicable; PR, partial response; SD, stable disease.

1

Unknown response of evaluable disease